Figure 1
Study design.Patients were non-randomized to the KD or control group. The observation period was 16 weeks (treatment phase), which was divided into the initial phase (first week) and maintenance phase (2nd to 16th week). Patients in the KD and control groups were followed by telephone (white arrow) and face-to-face interview (black arrow). Routine testing for blood and urine, liver and renal function, electrolytes and lipid profile was regularly performed in the KD group (grey circle).